Skip to content

News &
Events

news

29
April
2020
RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer
15
April
2020
Expanded Access Policy for Investigational product telitacicept
15
April
2020
FDA Grants Fast Track Designation to RemeGen’s Telitacicept as a Treatment for Systemic Lupus Erythematosus
2
April
2020
RemeGen Completes USD $100 Million Plus in Funding
15
November
2019
RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
Load more
For media inquiries, please contact Jennifer Gordon at
jgordon@spectrumscience.com